abemaciclib + temozolomide

Abemaciclib + temozolomide is an investigational combination therapy consisting of two small molecule drugs: abemaciclib, a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), and temozolomide, an oral alkylating agent. Abemaciclib inhibits cell cycle progression by blocking CDK4/6-mediated phosphorylation of the retinoblastoma protein, leading to G1 cell cycle arrest. Temozolomide induces DNA damage through methylation at the O6 and N7 positions of guanine, resulting in cytotoxicity in rapidly dividing tumor cells. This combination is being studied primarily for pediatric and young adult patients with relapsed or refractory solid tumors—including high-grade glioma—where preclinical data suggest additive or synergistic antitumor effects[2][3][7][8].

Other names

abemaciclib plus temozolomideabemaciclib and temozolomide